Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
Rev Assoc Med Bras (1992) ; 67(5): 696-701, 2021 Jun.
Article in English | MEDLINE | ID: mdl-34550258

ABSTRACT

OBJECTIVE: The aims were to compare the red blood cells, platelet count, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, red cell distribution width, and fasting glucose in peripheral blood of patients with benign and malignant uterine neoplasms and to relate these laboratory parameters with prognostic factors and overall survival in cancer. METHODS: The results of the laboratory parameters were analyzed using the Mann-Whitney U test. Receiver operating characteristic curves were used to find the cutoff values. Overall survival was estimated using the Kaplan-Meyer method. RESULTS: Higher values of neutrophil-lymphocyte ratio and fasting glucose were found in cancer patients. Higher platelet-lymphocyte ratio values were associated with other subtypes when compared with endometrioid subtype; higher values of red cell distribution width were found in stage II/IV when compared with stage I; lower hemoglobin values were related to stage II/IV and nonendometrioid histological type. Platelet-lymphocyte ratio <145.56 was associated with longer overall survival. CONCLUSION: Hemoglobin and platelet-lymphocyte ratio values are prognostic factors in uterine corpus cancer.


Subject(s)
Laboratories , Uterine Neoplasms , Female , Humans , Lymphocytes , Prognosis , Retrospective Studies
2.
Biomarkers ; 25(6): 474-482, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32544350

ABSTRACT

PURPOSE: The aim was to investigate the systemic levels of cytokines and the expression of the chemokine receptor CXCR2 in circulating neutrophils in patients with non-neoplastic ovarian lesions, benign neoplasia or malignant neoplasia. MATERIALS AND METHODS: Controls and patients with ovarian tumours were pre-operatively compared for the production of cytokines (IL-2, IL-5, IL-6, IL-8, IL-10 and TNF-α) by ELISA, and for the expression of the chemokine receptor, CXCR2, in neutrophils, by flow cytometry. Randomly selected patients within the malignant group were re-evaluated for the inflammatory parameters at 30 days after surgery. RESULTS: The serum concentrations of IL-6, IL-8 and IL-10 were significantly higher in the benign and malignant neoplasia than in the control group, and their levels were significantly higher in ovarian cancer patients than in patients with non-neoplastic tumours or benign neoplasia. Treatment reduced IL-8 serum levels but did not affect CXCR2 expression in neutrophils. Cut-off values for IL-6, IL-8, and IL-10 comparing malignant vs. benign neoplasia were 11.3, 71.7, 14.8, and comparing malignant neoplasm vs. non-neoplastic lesions were 7.2, 43.5, 12.3, respectively. CONCLUSIONS: Serum IL-6, IL-8, and IL-10 levels, and expression of CXCR2 in circulating neutrophils seem promising for distinguishing ovarian cancer patients from patients with benign tumours.


Subject(s)
Biomarkers, Tumor/blood , Cytokines/blood , Ovarian Neoplasms/blood , Receptors, Interleukin-8B/blood , Adult , Aged , Female , Gene Expression Regulation, Neoplastic/genetics , Humans , Interleukin-10/blood , Interleukin-2/blood , Interleukin-5/blood , Interleukin-6/blood , Interleukin-8/blood , Middle Aged , Neoplasms/blood , Neoplasms/pathology , Ovarian Neoplasms/pathology , Tumor Necrosis Factor-alpha/blood
3.
Rev Assoc Med Bras (1992) ; 66(1): 61-66, 2020.
Article in English | MEDLINE | ID: mdl-32130383

ABSTRACT

OBJECTIVE: To relate disease-free survival and overall survival with type I and type II ovarian cancer and preoperative laboratory parameters biomarkers. METHODS: A retrospective study was carried out based on the collection of data from medical records of patients with ovarian tumors. Kaplan-Mayer curves were drawn based on the statistical analysis of the data and were compared using the Log-rank test. RESULTS: Disease-free survival in type I ovarian cancer was significantly higher than in type II (p=0.0013), as well as in those with normal levels of CA-125 (p=0.0243) and with a platelet-lymphocyte ratio (PLR) lower than 200 (p=0.0038). The overall survival of patients with type I ovarian cancer was significantly higher than in patients with type II, as well as in patients with normal CA-125 serum levels (p=0.0039) and those with a preoperative fasting glucose of less than 100 mg/dL. CONCLUSION: CA-125 levels may predict greater overall and disease-free survival. PLR < 200 may suggest greater disease-free survival, whereas normal fasting glucose may suggest greater overall survival.


Subject(s)
Ovarian Neoplasms/blood , Ovarian Neoplasms/mortality , Adolescent , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/blood , CA-125 Antigen/blood , Disease-Free Survival , Female , Humans , Kaplan-Meier Estimate , Lymphocyte Count , Middle Aged , Neutrophils , Ovarian Neoplasms/pathology , Platelet Count , Predictive Value of Tests , Preoperative Period , Reference Values , Retrospective Studies , Young Adult
4.
Rev. Assoc. Med. Bras. (1992, Impr.) ; 66(1): 61-66, Jan. 2020. tab, graf
Article in English | LILACS | ID: biblio-1091900

ABSTRACT

SUMMARY OBJECTIVE To relate disease-free survival and overall survival with type I and type II ovarian cancer and preoperative laboratory parameters biomarkers. METHODS A retrospective study was carried out based on the collection of data from medical records of patients with ovarian tumors. Kaplan-Mayer curves were drawn based on the statistical analysis of the data and were compared using the Log-rank test. RESULTS Disease-free survival in type I ovarian cancer was significantly higher than in type II (p=0.0013), as well as in those with normal levels of CA-125 (p=0.0243) and with a platelet-lymphocyte ratio (PLR) lower than 200 (p=0.0038). The overall survival of patients with type I ovarian cancer was significantly higher than in patients with type II, as well as in patients with normal CA-125 serum levels (p=0.0039) and those with a preoperative fasting glucose of less than 100 mg/dL. CONCLUSION CA-125 levels may predict greater overall and disease-free survival. PLR < 200 may suggest greater disease-free survival, whereas normal fasting glucose may suggest greater overall survival.


RESUMO OBJETIVO Relacionar a sobrevida livre de doença e sobrevida global com câncer de ovário tipos I e II, assim como com parâmetros laboratoriais pré-operatórios biomarcadores. MÉTODOS Estudo retrospectivo realizado com base na coleta de dados de prontuários de pacientes com tumor ovariano. As curvas de Kaplan-Mayer foram realizadas em relação à análise estatística dos dados, sendo comparadas pelo teste de Log-rank. RESULTADOS A sobrevida livre de doença nas pacientes com câncer de ovário tipo I foi significativamente maior do que nas pacientes com câncer de ovário tipo II (p = 0,0013), bem como maior naquelas com níveis normais de CA-125 (p = 0,0243) e com relação plaquetas-linfócitos (RPL) inferior a 200 (p = 0,0038). A sobrevida global de pacientes com câncer de ovário tipo I foi significativamente maior do que em pacientes com tipo II, maior em pacientes com níveis séricos normais de CA-125 (p = 0,0039) e naquelas com glicemia de jejum pré-operatória menor que 100 mg / dL. CONCLUSÃO Os níveis de CA-125 podem predizer uma sobrevida global e livre de doença. A RPL < 200 pode sugerir uma maior sobrevida livre de doença, enquanto uma glicemia normal de jejum, uma maior sobrevida global.


Subject(s)
Humans , Female , Adolescent , Adult , Aged , Aged, 80 and over , Young Adult , Ovarian Neoplasms/mortality , Ovarian Neoplasms/blood , Ovarian Neoplasms/pathology , Platelet Count , Reference Values , Biomarkers, Tumor/blood , Predictive Value of Tests , Retrospective Studies , Lymphocyte Count , Disease-Free Survival , CA-125 Antigen/blood , Kaplan-Meier Estimate , Preoperative Period , Middle Aged , Neutrophils
5.
Immunol Invest ; 49(5): 510-521, 2020 Jul.
Article in English | MEDLINE | ID: mdl-31755326

ABSTRACT

The objectives of the study were to analyze the dosage of a cytokine panel (IL2, IL5, IL6, IL8, IL10, and TNF-α) in the peritoneal fluid and relate the dosage of these cytokines to prognostic para- meters and survival in ovarian cancer. Peritoneal fluid was collected intraopera- tively from 29 patients with primary malignant ovarian neoplasia. Cytokine panel dosing was performed with ELISA. Comparisons of cytokines with prognostic factors were performed using the Wilcoxon-Mann-Whitney test. ROC curves were used to determine the cutoff value of NLR, PLR, and IL6. Univariate and multivariate analysis of disease-free survival (DFS) or overall survival (OS) were performed (Kaplan-Meier and Cox regression). The differences were considered significant when the value of p < .05. Higher levels of IL-6 were related to a neutrophil-lymphocyte ratio (NLR) >3.18 (p = .04), a platelet-lymphocyte ratio (PLR) >219.23 (p = .0051), CA-125 levels >35 U/mL (p = .0019), stage IIIC (p = .0203), and DFS ≤ 24 months (p = .0267). For IL-8, higher levels were related to PLR > 219.23 (p = .0426), and CA-125 >35 U/mL (p = .0292). In the univariate analysis, IL-6 levels ≥87.23 in peritoneal fluid had a relationship with shorter DFS at significance threshold (p = .05), and with a shorter OS (p = .039). Multivariate survival analysis proved that IL-6 level in the peritoneal fluid was an independent predictor of OS. Therefore, IL-6 and IL-8 in peritoneal lavage were related to poor prognostic factors. These cytokines may represent new biomarkers for ovarian cancer therapies.


Subject(s)
Ascitic Fluid/metabolism , Biomarkers, Tumor/metabolism , Interleukin-6/metabolism , Interleukin-8/metabolism , Ovarian Neoplasms/diagnosis , Adolescent , Adult , Aged , Aged, 80 and over , Cytokines/metabolism , Female , Humans , Lymphocytes/immunology , Middle Aged , Neoplasm Staging , Ovarian Neoplasms/mortality , Prognosis , Survival Analysis , Young Adult
6.
J Obstet Gynaecol ; 40(3): 401-405, 2020 Apr.
Article in English | MEDLINE | ID: mdl-31476946

ABSTRACT

The aim of this study was to evaluate cytokine levels (IL-2, IL-8, TNF-α, IL-5, IL-6 and IL-10) in the peritoneal fluid in non-neoplastic tumours, benign ovarian neoplasms and malignant ovarian neoplasms. Peritoneal fluid or ascites was collected from 117 patients with neoplastic and non-neoplastic ovarian tumours. Cytokine levels were assessed by ELISA. The unpaired groups were compared by the Kruskal-Wallis test with Dunn's post-test. Higher IL-6 levels were found in malignant neoplasms when compared to non-neoplastic tumours (p=.0241). There was no significant difference in the evaluation of other cytokines. Therefore, higher IL-6 levels in peritoneal fluid are related to the diagnosis of ovarian cancer. Further studies should be performed to evaluate the profile of cytokines in the peritoneal fluid of patients with ovarian tumours, and may be a new diagnostic strategy and a future target for treatment.Impact statementWhat is already known on this subject? Cytokines can be dosed in both the serum and peritoneal fluid, and in the ascitic fluid of women with ovarian neoplasia. Elevated levels of IL-6 were found in the ascitic fluid of patients with malignant ovarian tumours.What the results of this study add? To our knowledge, this is the first study in the literature that evaluates a large panel of cytokines in the peritoneal fluid (and not only in ascites), comparing non-neoplastic tumours, benign neoplasms and malignant ovarian neoplasms.What the implications are of these findings for clinical practice and/or further research? The cytokine dosage in the peritoneal fluid should be considered to map a profile of inflammatory cytokines that permeate the peritoneal cavity of patients with ovarian cancer. The dosage of these cytokines can be a potential pre-surgical tumour marker. In addition, a better understanding of the pattern of cytokines around ovarian neoplasia may be targeted for further studies in the development of new therapies for ovarian cancer.


Subject(s)
Ascites/metabolism , Ascitic Fluid/chemistry , Cytokines/analysis , Ovarian Neoplasms/metabolism , Adolescent , Adult , Aged , Ascites/pathology , Biomarkers, Tumor/analysis , Child , Enzyme-Linked Immunosorbent Assay , Female , Humans , Interleukin-10/analysis , Interleukin-2/analysis , Interleukin-5/analysis , Interleukin-8/analysis , Middle Aged , Ovarian Neoplasms/pathology , Tumor Necrosis Factor-alpha/analysis , Young Adult
7.
Gynecol Obstet Invest ; 83(1): 35-39, 2018.
Article in English | MEDLINE | ID: mdl-28494447

ABSTRACT

BACKGROUND/AIMS: Growth differentiation factor 15 (GDF-15) is induced by pro-inflammatory cytokines. Higher levels of GDF-15 have been associated with malignancy. The aim of the study was to evaluate both tissue and serum levels of GDF-15 in ovarian neoplasms. METHODS: A cohort study evaluated 31 patients with benign ovarian tumors and 34 patients with ovarian cancer were evaluated in 2 years. The inclusion criterion was histopathological diagnosis of ovarian epithelial neoplasia. Exclusion criteria were secondary malignant ovarian neoplasia and preoperative treatment. Serum and tissue levels of GDF-15 were assessed by enzyme-linked immunosorbent assay and immunohistochemistry, respectively. Chi-square test and unpaired t test were performed. RESULTS: Serum levels were higher in the patients with malignant neoplasms than in the patients with benign tumors, yet the difference was not statistically significant. GDF-15 immunostaining was significantly more frequent in the stroma of the malignant tumors than in the stroma of the benign tumors (p = 0.0034). CONCLUSION: GDF-15 staining is elevated in the stroma of ovarian cancer, demonstrating that it may be a potential diagnostic and therapeutic target.


Subject(s)
Growth Differentiation Factor 15/analysis , Ovarian Neoplasms/chemistry , Stromal Cells/metabolism , Adult , Aged , Cohort Studies , Enzyme-Linked Immunosorbent Assay , Female , Growth Differentiation Factor 15/blood , Humans , Immunohistochemistry , Middle Aged , Ovarian Neoplasms/blood , Ovarian Neoplasms/pathology
8.
Immunol Invest ; 46(7): 677-688, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28872976

ABSTRACT

The aim of the study was to correlate serum levels of IL-2, IL-5, IL-6, IL-8, IL-10, and TNF-α with clinical, laboratory, and pathological prognostic factors in patients with primary ovarian malignancy. Patients treated at the Pelvic Mass Ambulatory of the Discipline of Gynecology and Obstetrics/Oncology Research Institute (IPON) of the UFTM with confirmed diagnosis of malignant ovarian neoplasia (n = 26) were evaluated. Serum collection was performed preoperatively for the determination of tumor markers. The cytokines IL-2, IL-5, IL-6, IL-8, IL-10, and TNF-α were assayed by enzyme-linked immunosorbent assay (ELISA). The prognostic factors were compared using the Mann-Whitney test, with significance level lower than 0.05. When evaluating IL6, it was observed that higher serum levels were associated with overall survival less than 60 months (p = 0.0382). In the evaluation of IL8, higher serum levels were associated with neutrophil-to-lymphocyte ratio (NLR) ≥ 4 and platelet-to-lymphocyte ratio (PLR) ≥ 200 (p = 0.0198 and p = 0.0072, respectively), altered values of serum CA125 (p = 0.0457), and stage IIIC (p = 0.0486). Therefore, increased levels of IL-6 and IL-8 are associated with factors of worse prognosis in ovarian cancer. Additional studies with a larger sample of patients are needed to confirm the role of cytokines as prognostic factors, in the definition of treatment, and in the development of future target therapies.


Subject(s)
Cystadenocarcinoma, Serous/immunology , Cystadenoma, Mucinous/immunology , Granulosa Cell Tumor/immunology , Interleukin-6/blood , Interleukin-8/blood , Neutrophils/immunology , Ovarian Neoplasms/immunology , Adult , Aged , Biomarkers, Tumor/blood , Cystadenocarcinoma, Serous/diagnosis , Cystadenocarcinoma, Serous/mortality , Cystadenoma, Mucinous/diagnosis , Cystadenoma, Mucinous/mortality , Cytokines/blood , Enzyme-Linked Immunosorbent Assay , Female , Granulosa Cell Tumor/diagnosis , Granulosa Cell Tumor/mortality , Humans , Middle Aged , Neoplasm Staging , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/mortality , Prognosis , Survival Analysis
9.
Case Rep Infect Dis ; 2017: 6401694, 2017.
Article in English | MEDLINE | ID: mdl-28487789

ABSTRACT

Pelvic tuberculosis is a type of extrapulmonary tuberculosis. The disease is accompanied by clinical and laboratory findings which may be unspecific and present aspects of other diseases, including gynecological malignancies. In this report, the authors presented a case of pelvic tuberculosis associated with peritoneal tuberculosis in a young woman exhibiting imaging and tumor markers consistent with ovarian neoplasm. An intraoperative frozen section analysis detected atypical cells that were suggestive of ovarian borderline or malignant epithelial neoplasia. The pathological analysis showed granulomatous inflammation in the right ovary and fallopian tube with a pattern of mycobacteriosis that was consistent with the presence of mycobacteria morphologically compatible with Mycobacterium tuberculosis. The patient had a complete remission after the use of antituberculosis drugs.

10.
Clin Med Insights Oncol ; 10: 71-6, 2016.
Article in English | MEDLINE | ID: mdl-27512342

ABSTRACT

INTRODUCTION: Ovarian cancer has a high mortality and delayed diagnosis. Inflammation is a risk factor for ovarian cancer, and the inflammatory response is involved in almost all stages of tumor development. Immunohistochemical staining in stroma and epithelium of a panel of cytokines in benign and malignant ovarian neoplasm was evaluated. In addition, immunostaining was related to prognostic factors in malignant tumors. METHOD: The study group comprised 28 ovarian benign neoplasias and 28 ovarian malignant neoplasms. A panel of cytokines was evaluated by immunohistochemistry (Th1: IL-2 and IL-8; Th2: IL-5, IL-6, and IL-10; and TNFR1). Chi-square test with Yates' correction was used, which was considered significant if less than 0.05. RESULTS: TNFR1, IL-5, and IL-10 had more frequent immunostaining 2/3 in benign neoplasms compared with malignant tumors. Malignant tumors had more frequent immunostaining 2/3 for IL-2 in relation to benign tumors. The immunostaining 0/1 of IL 8 was more frequent in the stroma of benign neoplasms compared with malignant neoplasms. Evaluation of the ovarian cancer stroma showed that histological grade 3 was significantly correlated with staining 2/3 for IL-2 (P = 0.004). Women whose disease-free survival was less than 2.5 years had TNFR1 stromal staining 2/3 (P = 0.03) more frequently. CONCLUSION: IL-2 and TNFR1 stromal immunostaining are related prognostic factors in ovarian cancer and can be the target of new therapeutic strategies.

11.
Immunol Lett ; 158(1-2): 195-9, 2014.
Article in English | MEDLINE | ID: mdl-24447864

ABSTRACT

The study related the immunohistochemical staining of cytokines (IL2, IL5, IL6, IL8, IL10, and TNF-alpha), and iNOS staining with clinical and pathological parameters of patients with primary ovarian malignancy. We prospectively evaluated 40 patients who underwent surgical treatment in accordance with pre-established criteria and later confirmed diagnosis of ovarian cancer. Immunohistochemistry study for cytokines (IL2, IL5, IL6, IL8, IL10, TNF-alpha) and iNOS was performed. The evaluation of prognostic factors was performed using the Fisher's exact test. The significance level was less than 0.05. Histological grade 1 was significantly correlated with strong intensity for TNF-α (p=0.0028). In addition, early stages showed strong expression intensity of TNF-α, but this was at the limit of significance (p=0.0525). Strong staining immunohistochemical IL5 was related to disease-free survival less than or equal to 24 months, suggesting that a factor of poor prognosis, but there was no statistical significance (p=0.1771). There was no statistical significance in relation at other cytokines studied. Therefore, immunohistochemical staining in strong intensity for TNF-α was related to histological grade 1 and early stages of ovarian cancer in our sample of patients.


Subject(s)
Carcinoma/diagnosis , Cytokines/metabolism , Nitric Oxide Synthase Type II/metabolism , Ovarian Neoplasms/diagnosis , Adult , Carcinogenesis , Carcinoma/immunology , Carcinoma/mortality , Disease-Free Survival , Female , Follow-Up Studies , Humans , Immunohistochemistry , Middle Aged , Neoplasm Staging , Ovarian Neoplasms/immunology , Ovarian Neoplasms/mortality , Prognosis , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...